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Antonio Entrena1 & Luisa Carlota López-Cara1
A novel family of compounds derivative of 1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))
bis(methylene))-bispyridinium or –bisquinolinium bromide (10a-l) containing a pair of oxygen atoms in 
the spacer of the linker between the biscationic moieties, were synthesized and evaluated as inhibitors 
of choline kinase against a panel of cancer-cell lines. The most promising compounds in this series were 
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) 
bromide (10a) and 1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bis(7-chloro-
4-(pyrrolidin-1-yl)quinolinium) bromide (10l), which inhibit human choline kinase (ChoKα1) with 
IC50 of 1.0 and 0.92 μM, respectively, in a range similar to that of the previously reported biscationic 
compounds MN58b and RSM932A. Our compounds show greater antiproliferative activities than do 
the reference compounds, with unprecedented values of GI50 in the nanomolar range for several of the 
cancer-cell lines assayed, and more importantly they present low toxicity in non-tumoral cell lines, 
suggesting a cancer-cell-selective antiproliferative activity. Docking studies predict that the compounds 
interact with the choline-binding site in agreement with the binding mode of most previously reported 
biscationic compounds. Moreover, the crystal structure of ChoKα1 with compound 10a reveals that this 
compound binds to the choline-binding site and mimics HC-3 binding mode as never before.
Cancer is a worldwide health threat and the second leading cause of mortality in developed countries1,2. Since 
many of the current treatments still prove toxic and/or lead to drug resistance, there is a strong demand for the 
discovery and development of effective new cancer therapies3.
Protein kinases have emerged as one of the most important types of targets in cancer-drug discovery due to 
their major roles in regulating cell growth and survival and many other cell functions4,5. An abnormal kinase sig-
naling network underlies the development and progression of tumors, and thus the targeted inhibition of protein 
kinases has become an attractive strategy in cancer treatment (for a recent review see Gross et al.6) and in the last 
decade the intense development in the field has led to different kinase inhibitors that have been approved for use 
in clinical therapy.
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Choline kinase (ChoK) (EC 2.7.1.32) catalyzes the phosphorylation of choline by ATP in the presence of 
Mg2+ to yield phosphocholine (PCho) and ADP7,8. This step introduces choline to the so-called Kennedy or 
CDP-choline pathway for the biosynthesis of phosphatidylcholine, which represents the most abundant class 
of phospholipids in eukaryotic cells, constituting 40–60% of the phospholipids content in cell membranes9. In 
addition to forming the major structural component of the membrane bilayer, phosphatidylcholine also serves as 
a precursor for the production of lipid second messengers10.
Mammalian ChoK exists as three isoforms, encoded by two separate genes11,12. In humans, ChoKα 1 (457 
amino acids) and ChoKα 2 (439 amino acids) derive from a single gene (chk-α) by alternative splicing, while 
ChoKβ (395 amino acids) is the product of a different gene (chk-β). The amino acid sequence identity is 56% 
between ChoKα and ChoKβ , and both chk-α and chk-β mRNAs, as well as their encoded protein isoforms, are 
ubiquitously expressed in diverse tissues13. Each isoform is present as either dimers (homo- or hetero-) or as 
tetramers in solution and is not active in monomeric form7, suggesting that, for higher eukaryotes, dimeric ChoK 
is the minimum functional form.
Choline kinase is overexpressed in many tumors such as breast, lung, bladder, colon, prostate, ovary, and liver 
carcinomas14–16 and recently elevated enzymatic activity has also been shown in T-lymphoma17. This increasing 
expression leads to abnormal choline metabolism, resulting in higher phosphocholine levels, which refer to a 
cholinic phenotype associated with oncogenesis and tumor progression18. As a result, ChoKα , has become an 
attractive target for novel anticancer therapies.
The determination of the crystal structures of ChoK proteins from Caenorhabditis elegans and human, in 
which two monomers were dimerized in each asymmetric unit19,20 and the correct identification of ATP and 
choline binding sites into crystal structure of human ChoKα 2 isoform, have enabled the design and the syn-
thesis of a series of asymmetrical molecules as potential ChoK inhibitors and antiproliferative compounds21,22. 
Figure 1 shows HC-3, the first inhibitor of choline kinase described, MN58b and RSM923A, which belong to the 
first generation of Chok inhibitors23–28, and the most promising compounds developed by our group. Note that 
RSM932A (also called TCD-717) has evidenced a low-toxicity profile with improved tolerability in mice29 and a 
Phase I clinical trial has just been completed for the treatment of advanced solid tumors (http://clinicaltrials.gov/
ct2/show/NCT01215864).
For compounds 1 and 2, we identified the adenine and 1-benzyl-4-(dimethylamino)pyridinium as the most 
efficient fragments of these molecules by the deconvolution approach based on the ChoKα 1/1 (PDB ID: 3ZM9)30 
and ChoKα 1/2 (PDB ID: 4BR3)31 crystal structures, demonstrating that the adenine fragment occupies the ATP 
binding site and that the pyridinium fragment, through its positive charge delocalized over the nitrogen atom, 
mimics the positive charge present in choline or in HC-3.
The second generation of inhibitors (compounds 3 and 4), asymmetrical bispyridinium compounds, proved to 
be good inhibitors and provide the discovery of a new inhibitory binding site on ChoKα 1 Compound 4 (Fig. 1), 
which induced the opening of new adjacent binding site where the 4-Chloro-N-methylaniline fragment is located, 
adopting an unprecedented modality of binding to ChoKα 1(ChoKα 1/4, PDB ID: 4CG8)32, while compound 3 
(with biphenyl group as a linker) adopts a binding mode similar to the one observed for compound 2.
In an effort to produce additional highly active compounds, we focused on longer spacers between biphe-
nilic or bipyridinic rings, which have electron donor or acceptor groups necessary to increase the binding to the 
enzyme through of hydrogen bonds and the solubility, while retaining some inhibition properties.
Figure 1. Structure of compounds HC-3, MN58b, RSM932A and structures of symmetrical and non-
symmetrical inhibitors of choline kinase previously published (compounds 1–5). General structure of 
compounds 10a-l described in this paper.
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Deep modeling and virtual screening studies32–34 have suggested the interaction with the choline binding 
site in the ChoKα 1/4 complex while keeping the biscationic structure unchanged. Thus a classical bioisosteric 
exchange between carbon and oxygen atoms could increase, on one hand, the polarity and the solubility of these 
compounds and, on the other hand, the affinity for the enzyme due to the synclinal conformation of the linker 
of these molecules. In this way, in the present study, we reconfigured the substitution pattern around linker moi-
ety by the preparation of 1,1′ -(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bis[4-pyridinium 
or quinolinium] bromide derivatives with general structures 10a-l (Fig. 1). MN58b, RSM932A, 1, 2, 3, 4, our 
recently published compound 535 (Fig. 1) and the most active compounds described by S. Trousil36, were taken as 
patterns to improve the polarity and solubility, while also improving inhibition by the enzyme and consequently 
enhancing the antiproliferative effect. This series was obtained by interchanging the substitution pattern of linker 
by the introduction of two oxygen atoms in the linker, in order to determine the influence of these groups on the 
antiproliferative and inhibitory activity of ChoKα 1, using various cationic heads previously synthesized by our 
group in similar compounds. We fixed the most successful cationic heads described previously (pyridinium and 
quinolinium salts)32,35–40 and examined several 4-substitutions with alkylamines or phenylamines on the aryl-
moiety. Also, we introduced a quinuclidinium salt, which mimics the trimethylammonium of the choline, but 
potentially prevents interactions with the cholinergic system41.
Results and Discussion
Chemistry. Microwave-assisted reactions present several advantages, such as a remarkable reduction in reac-
tion times compared to those of the conventionally heated reactions and often lead to improved yields42,43. In the 
present work, we describe the use of microwave irradiation as an energy source for the synthesis of the interme-
diate (7 and 8) of twelve 1,2-bis(p-methylphenoxy)ethane derivatives 10a-l, substituted in the methylphenoxy 
group with different cationic heads as moieties. These compounds can be also considered as more polar analogues 
of choline kinase inhibitor derivatives than those previously synthesized.
The syntheses of compounds 10a-l is shown in Fig. 2, and follows three easy steps. The first is the treatment 
of the 4-methylphenol (6) in ethanol with NaOH (1.1 equiv) stirring at room temperature for 30 min, followed 
by the addition of 1,2-dibromoethane (0.5 equiv), under microwave irradiation (130 °C, 28 min) to provide the 
1,2-bis(p-methylphenoy)ethane (7)44,45. Then, bromination in the methylene of 7 with NBS and dibenzoylperox-
ide in CCl4 also under microwave irradiation (120 °C, 21 min), to give the 1,2-bis(4-bromomethylphenoy)ethane 
(8)45,46. In comparison with conventional (thermal) heating, the microwave heating reduced the reaction time in 
both reactions (30 min vs. 8 h and 21 min vs. 5 h, respectively), but we also noted some yield improvement (35% 
vs. 21% and 65% vs. 39%, respectively)45,46.
We conducted different experiments to achieve these successful results with the MW (Table S1 of 
Supplementary information). Although in the second step, we were restricted by the quantity to use, since using 
only 100 mg of derivative 7 gave the best yields, while more quantity of 7 led to diminished yields. This result was 
Figure 2. General synthetic pathway followed in the preparation of compounds 10a-l i) NaOH, EtOH, RT 30 min. 
ii) Br-(CH2)2-Br, MW, 130 °C, 28 min. iii) NBS, CCl4, dbp, MW 130 °C, 21 min. iv) 10a-l, CH3CN, 72 hours.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:23793 | DOI: 10.1038/srep23793
due to the volume of the reactor, which allows only 5 mL of the mixture, while more than 100 mg of 7 derivative 
would need more solvent to dissolve it.
Finally, the last step is the introduction of cationic heads (previously synthesized using the procedure 
reported32,35–40 by means of a simple SN2 reaction in acetonitrile under argon atmosphere for 72 h at reflux of 
1,2-bis(4-bromomethylphenoxy)ethane (8) and the 4-substituted pyridine derivative (9a-c), quinuclidine deriv-
ative (9d-e) or 4-substituted quinoline or 7-Chloro-4-substituted quinoline (9f-l) to afford 10a-l with moderate 
or good yields46.
Docking studies. Docking studies were made in order to design the new ChoK inhibitors. The crystal struc-
tures of greatest interest for docking studies are those of ChoKα 1 isoenzyme in complex with compounds 2 (PDB 
ID: 4BR3)31 and 4 (PDB ID: 4CG8)32, since the cationic heads of compounds described in this paper are similar 
to those of compounds 2 and 4.
Figure 3A shows compound 2 (carbon atoms in yellow color) inserted into the Cho binding site, being stabi-
lized by cation-π interactions with Tyr333, Tyr354, Tyr440, Trp420, Trp423, and Phe435 (carbon atoms in cyan 
color). In particular, the biphenyl group shows optimal parallel hydrophobic stacking interactions with Tyr354, 
and the 4-(dimethylamino)pyridinium moiety interacts through parallel cation-π interaction with Trp420. The 
orientation of this compound inside the Cho binding site was accommodated by a conformational change of 
Tyr333, which moved back to create an extra space30,31. The adenine fragment of compound 2 inserted into the 
Cho binding site was outside the enzyme and showed no interaction with the protein (Figure S1 of Supplementary 
information), 1-(biphenyl-4-ylmethyl)-4-(dimethylamino)pyridinium being the key fragment of this compound 
for the interaction at the Cho binding site30,31. Figure 3B shows compound 4 (carbon atoms in orange color) 
inserted into the ChoKα 1 crystal structure. This compound adopts a new different binding mode, inducing a 
conformational change in some amino acids. Tyr256, Tyr333, and Trp420 are the residues that undergo the major 
changes, and the rotation of these side chains is critical to allow the insertion of the 4-chloro-N-methylaniline 
fragment into an additional binding site (carbon atoms in magenta color), being stabilized by hydrophobic inter-
actions with Trp248, Tyr256, Tyr333, Leu419, Trp420, and Trp423. The rest of the molecule is located inside the 
Cho binding site (carbon atoms in cyan color), the pyridinium moieties being stabilized through cation-π inter-
actions with Tyr333, Tyr354, Trp420, and Tyr44032. Compound 4 is more inserted into the Cho binding site in 
Figure 3. (A) Crystal structure of ChoKα 1/2 complex (PDB ID: 4BR3). Compound 2 (carbon atoms in yellow 
color) is inserted into the Cho binding site (carbon atoms in cyan color). (B) Crystal structure of ChoKα 1/4 
complex (PDB ID: 4CG8). Compound 4 (carbon atoms in orange color) is inserted into the Cho binding 
site (carbon atoms in cyan color) and in an additional binding site (carbon atoms in magenta color) that has 
been open by a conformational change of Tyr256, Tyr333, and Trp420 sidechains, induced by the insertion of 
compound 4 into the enzyme. (C) Resulting pose of compound 10a (carbon atoms in green color) in the Cho 
binding site of the ChoKα 1/2 crystal structure, and D) Resulting pose of compound 10l (B, carbon atoms in 
yellow color) in the ChoK binding site of the ChoKα 1/4 crystal structure.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:23793 | DOI: 10.1038/srep23793
comparison to compound 2 (Figure S1 of Supplementary Information) since this compound makes the complete 
opening of this site.
Docking studies have been performed in both crystal structures and the analysis of the resulting poses indi-
cates which compounds could be similar to compound 2 or to compound 4. In fact, compounds 10a, 10b, 10d, 
and 10e have shown good poses in the crystal structure of compound 2, while the correct poses of compounds 
10c, 10f, 10g, 10h, 10i, 10j, 10k, and 10l resulted in the crystal structure of compound 4.
As an example, Fig. 3C,D show the resulting pose of compounds 10a and 10l. Compound 10a (carbon atoms 
in green color) has two 4-(dimethylamino)pyridinium cationic heads, similarly to compound 2 (Fig. 3A). One 
1-benzyl-4-(dimethylamino)pyridinium fragment is inserted in a way very similar to that of compound 2: i) 
the cationic head is situated close to Trp420, being stabilized by π -cation interactions with Trp420, Tyr333, and 
Trp423; and: ii) the benzyl fragment is also optimized by hydrophobic stacking interactions with Tyr354. The 
linker of compound 10a is extremely long, and the second 1-benzyl-4-(dimethylamino)pyridinium fragment 
is situated outside of the enzyme, an additional hydrophobic interaction occurring between the second phe-
nyl fragment and Ile433. Compound 10l (carbon atoms in orange color) has two 7-chloro-4-(pyrrolidin-1-yl)
quinolinium) cationic heads, one of which is inserted very similarly to compound 4 (Fig. 3B): the 4-pyrrolidin 
fragment is inserted into the additional binding site and stabilized by hydrophobic interactions, while the 
7-chloroquinolinium moiety is situated into the Cho binding site and stabilized by cation-π interactions. The 
second cationic head is also inserted into the protein, being stabilized by hydrophobic interactions with Ile433 
and Arg117, and the phenyl group connected to this cationic head is also stabilized by cation-π interaction with 
Phe435. The most notable effect in these molecules is the conformation of the linker, since the 1,2-dioxoethane 
fragment adopts a synclinal conformation due to the gauche effect of the O-C-C-O bonds. This conformation of 
the linker allows the total insertion of compound 10l inside the Cho binding site, and also favors the insertion of 
compound 10a.
Figure S2 of Supplementary Information shows the resulting pose of compounds 10b, 10d, and 10e. The pose 
of compound 10b is very similar to that of compound 10a, the pyridinium moiety being slightly more separated 
from Tyr333 due to the higher volume of the pyrrolidine fragment, but the interaction of the whole molecule with 
the Cho binding site is very similar to that of compound 10a. Compound 10d shows also a similar pose to that of 
compound 10a, though slightly more inserted into the Cho binding site due to the smaller volume of the quinu-
clidine cationic head. The resulting pose of compound 10e is also similar, being slightly outside compound 10a 
due to the establishment of two H-bond between the 3-OH groups and Asn305 and Glu434, respectively. Figure 
S3 of Supplementary Information shows the resulting pose of compounds 10f-k and 10c. Compounds 10f-k have 
shown a pose very similar to that of compound 10l (Fig. 3D), one of the cationic heads being inserted inside the 
additional binding site and into the Cho binding site. The second cationic head is also inserted into the protein 
being stabilized by hydrophobic interactions with Arg117 and Ile433, and the phenyl group of this cationic head 
is also stabilized by  π -cation interaction with Phe435. The resulting pose of compound 10c shows a slight dif-
ference. This compound has two 4-((4-chlorophenyl)(methyl)amino)pyridinium cationic heads. One cationic 
head is also inserted into the additional binding site and into the choline binding site, as in compound 4, and the 
second cationic head is also inserted into the enzyme, but with a different orientation. Nevertheless, the most 
noteworthy effect is that in the resulting pose of these compounds the 1,2-dioxoethane fragment also adopted a 
synclinal conformation and, for this reason, all these compounds should be completely inserted into the enzyme 
and probably will show good ChoKα 1 inhibition.
Inhibition of ChoKα1 enzymatic activity. It has been reported that a potent anticancer effect inducing 
maximal apoptosis is achieved only when ChoKα 1 expression is specifically knocked down, without affecting 
ChoKβ levels47. Thus, in an initial step we evaluated whether these compounds have a selective behaviour on 
ChoKα 1.
We selected the most representative compounds of each family, (10a for pyridinium compounds and 10f, 
10g, 10k, and 10l for quinolinium compounds) and, since selectivity may be explained by a reduced flexibility 
of Trp353 in ChoKβ compared to its homologue Trp420 in ChoKα 1, as was proposed for HC-331, tryptophan 
fluorescence assays were performed (Figure S4 of Supplementary information). As expected from their chemical 
structures similar to that of compound 4, the results of the spectroscopy analysis, depicted in Table 1, showed 
that the Kd values of these compounds for ChoKα 1 were in the low μM range (0.241–0.700 μM), indicating high 
affinity for the enzyme. These results agree with the first experimental validation of the docking studies described 
above.
Compound HsChoKα1 Kd (μM)a
10a 0.700 ± 0.080
10f 0.295 ± 0.127
10g 0.517 ± 0.099
10k 0.241 ± 0.03
10l 0.357 ± 0.039
4 0.110 ± 0.01
HC-3 0.18 ± 0.03
Table 1.  Kd values of selected compounds evaluated by tryptophan fluorescence quenching. aKd values of 
indicated compounds for ChoKα 1 are expressed as mean ± S.D. of at least three independent experiments.
www.nature.com/scientificreports/
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Table 2 summarizes the clog P calculated by Pallas (3.8.1.1. PrologP) and the inhibitory effect on purified 
human ChoKα 1 activity.
Of all tested compounds, the ones that present an alkylamine or a cycloalkylamine substituted at position 4 of 
the pyridinium or quinolinium system, 10a-b and 10j-l, offer the best results in terms of enzyme inhibition and 
antiproliferative assays.
Regarding ChoKα 1 inhibitory effect, all compounds showed a micromolar activity, comparable to that of 
the two reference compounds RSM932A and MN58b. The docking studies indicated that all compounds could 
be inserted into the choline binding site and could be grouped into two families on the basis of their different 
insertion modes. Compounds 10a, 10b, 10d, and 10e could be inserted similarly to compound 2. Compound 10a 
showed good HsChoKα 1 inhibition (IC50 = 1.0 μM), thanks to the presence of the 1-benzyl-4-(dimethylamino)
pyridinium fragment, which performs a strong π -cation interaction with the Cho binding site (Fig. 3C), this 
having been described as one of the most efficient moieties for ChoKα 1 inhibition33. Compound 10b showed 
a reduced ChoKα 1 inhibition (IC50 = 9.56 μM) attributable to the volume of the 4-(pyrrolidin-1-yl)pyridin-
ium cationic head, causing a decrease in the π -cation interaction (Figure S2A). In this family, compound 10d 
showed very poor ChoKα 1 inhibition (IC50 = 37.54 μM). This result may be due to the presence of the qui-
nuclidine and the consequently low lipophilicity (clog P = −1.01) cationic head that probably prevented the 
interactions with Tyr333, Tyr354, Trp420, and Tyr440 (Figure S2B). However, although compound 10e had a 
3-hydroxyquinuclidine cationic head and low lipophilicity (clog P = −2.42), it showed better ChoKα 1 inhibi-
tion (IC50 = 9.51 μM) than could be explained by the establishment of two additional H-bonds with the enzyme 
(Figure S2C).
In summary, when compounds bind to the choline site, such as compound 2 (compound 10a-b, d-e), low 
lipophilicity values are sufficient to achieve good inhibition of the enzyme, the pydidinic ring being the most 
appropriate moiety, and the quinuclidine ring decreases the activity unless the lack of aromatic ring is offset by 
the formation of a H bond provided by the hydroxyl group.
The second group interacted with the choline binding site as compound 4. Compounds 10c 10j-l showed a 
good ChoKα 1 inhibition (IC50 = 1.63, 1.66, 2.02 and 0.92 μM respectively), while compounds 10f-i showed a 
slightly reduced ChoKα 1 inhibition (IC50 = 6.85, 3.27, 2.79 and 16.22 μM, respectively). All these compounds 
had a 4-substituted and 7-substituted quinolinium cationic head, 10f-l, except 10c, which had the rest of the 
N-methylanilino at the 4 position of the pyridinium cationic head. The structure of the 4-substituted fragment 
conditions the inhibitory activity of these molecules. In fact, compounds 10j-l had a 4-cycloalkylamino fragment, 
while compounds 10c and 10f-i had a 4-N-methylanilino substituent. The resulting IC50 values indicated that the 
4-cycloalkylamino favored the ChoKα 1 inhibition, probably promoting a more effective insertion into the addi-
tional binding site. In this group the chloro atom increased the volume of molecule and the lipophilicity. Thus, 
the compound 10l offered the right balance between volume and lipophilicity. The perhydroazepine group (10i) 
provided the volume to be inserted into the choline binding site properly and the addition of a choro atom slightly 
depressed the activity (10j).
Conversely, the compounds with an N-methylanilino system at the 4 position of the pyridinium or quinolin-
ium cationic heads showed lower IC50 than did those in the alkylamine system. In these compounds, the chloro 
atom in para position of 4-(methyl(phenyl)amino)quinolinium or pyridinium fragment (10c, 10g and 10i) or in 
position 7 of the quinolinium ring (10h and 10i) seemed to play an essential role in the enzyme inhibition. In fact, 
the presence of the chloro atom allowed the cationic head to be accommodated at the choline-binding site, likely 
by an increase in the lipophilicity provided by the halogen atom, regardless of where the halogen was located (10c, 
10g, and 10h IC50 = 1.63, 3.27, and 2.79 μM, respectively). A direct correlation between volume-lipophilic activity 
Comp.
clogP 
Ann 2005
aIC50 (μM) 
ChoKα1 purified
Antiproliferative activity bGI50 (μM)
HeLa HT−29 Jurkat HL-60 RS4,11 MCF-7 PC-3 A549 MDA-MB-231
10a −0.36 1.00 ± 0.01 0.079 ± 0.024 0.11 ± 0.01 0.12 ± 0.08 0.10 ± 0.04 0.045 ± 0.005 0.092 ± 0.019 0.051 ± 0.01 0.027 ± 0.010 0.10 ± 0.05
10b 0.36 9.56 ± 1.45 0.082 ± 0.041 4.3 ± 0.42 0.068 ± 0.016 0.042 ± 0.005 1.12 ± 0.22 0.17 ± 0.032 4.5 ± 1.1 2.3 ± 1.1 0.09 ± 0.02
10c 1.8 1.63 ± 0.14 5.6 ± 0.25 4.3 ± 1.1 7.3 ± 0.50 2.1 ± 0.6 2.7 ± 0.13 3.5 ± 0.72 3.1 ± 0.7 4.9 ± 0.7 2.2 ± 0.27
10d −1.01 37.54 ± 4.45 16.9 ± 2.5 >100 >100 84.1 ± 7.4 37.5 ± 4.2 91.4 ± 7.6 94.3 ± 12.4 61.3 ± 16.7 74.3 ± 2.6
10e −2.42 9.51 ± 1.14 >100 94.0 ± 4.2 >100 >100 66.0 ± 6.6 50.9 ± 11.7 48.0 ± 1.1 >100 63.2 ± 3.9
10f 3.02 6.85 ± 0.81 0.15 ± 0.031 0.12 ± 0.017 0.060 ± 0.002 0.063 ± 0.013 0.24 ± 0.05 0.17 ± 0.065 0.47 ± 0.12 0.21 ± 0.06 0.001 ± 0.001
10g 3.56 3.27 ± 0.66 0.25 ± 0.06 0.75 ± 0.12 0.098 ± 0.031 0.71 ± 0.24 0.15 ± 0.04 0.46 ± 0.063 0.26 ± 0.01 0.11 ± 0.018 0.19 ± 0.009
10h 3.82 2.79 ± 0.17 0.32 ± 0.062 0.35 ± 0.07 0.31 ± 0.07 0.92 ± 0.06 0.026 ± 0.006 0.32 ± 0.04 0.85 ± 0.32 0.18 ± 0.08 0.23 ± 0.04
10i 4.23 16.22 ± 0.44 1.5 ± 0.73 1.0 ± 0.15 0.76 ± 0.26 0.87 ± 0.28 0.50 ± 0.09 0.66 ± 0.07 0.72 ± 0.09 0.29 ± 0.10 0.15 ± 0.05
10j 2.27 1.66 ± 0.09 0.17 ± 0.084 0.15 ± 0.08 0.11 ± 0.026 0.42 ± 0.22 0.16 ± 0.012 0.11 ± 0.047 0.09 ± 0.04 0.30 ± 0.068 0.01 ± 0.005
10k 2.76 2.02 ± 0.08 0.26 ± 0.074 0.27 ± 0.05 0.072 ± 0.013 0.18 ± 0.06 0.036 ± 0.008 0.28 ± 0.09 0.11 ± 0.028 0.52 ± 0.02 0.061 ± 0.003
10l 2.36 0.92 ± 0.01 0.37 ± 0.18 0.56 ± 0.21 0.007 ± 0.003 0.16 ± 0.07 0.42 ± 0.14 0.022 ± 0.007 0.8 ± 0.2 0.14 ± 0.06 0.05 ± 0.02
MN58b 0.01 0.78 ± 0,03 1.9 ± 0.1 1.9 ± 0.4 0.35 ± 0.1 0.32 ± 0.03 1.0 ± 0.3 1.8 ± 0.06 n.d. 0.54 ± 0.2 0.31 ± 0.12
RSM932A 2.92 1.92 ± 0,06 0.83 ± 0.1 0.4 ± 0.2 0.41 ± 0.1 0.93 ± 0.1 0.17 ± 0.04 0.18 ± 0.10 n.d. 0.45 ± 0.09 0.17 ± 0.05
Table 2. In vitro inhibitory effects of compounds 10a-l. aIC50 = Compound concentration required to inhibit 
ChoKα 1 enzyme by 50%. bGI50 = Compound concentration required to inhibit tumor-cell proliferation by 50%. 
Values are the mean ± SEM for three independent experiments. n.d. not determined.
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was found in these compounds (10c, 10f-i), so that the less bulky and lipophilic compounds offered the best 
values (10c, ChoKα 1, IC50 = 1.66 μM, clog P = 1.8) while adding a second aromatic ring slightly diminished the 
activity of 10f-h. On the other hand, the two chloro atoms present in compound 10i made the molecule too bulky 
to bind to the choline site, lowering its inhibition activity (ChoKα 1, IC50 = 16.22 μM), and raising its lipophilic-
ity (clog P = 4.23). However, the absence of chloro atom in 10f also considerably decreased ChoKα 1 inhibition 
(IC50 = 6.85 μM), highlighting the important role of the chloro atom.
Regardless the binding mode to the enzyme, the best inhibitory activities were found when a fragment of 
alkylamine or cycloalkylamine was present at the 4 position in pyridinium or quinolinium cationic heads, such as 
10a, 10j, 10k, and 10l (IC50 = 1.0, 1.66, 2.02, and 0.92 μM, respectively), These results reveal that the volume of the 
cationic head probably fits properly into the choline binding site. The only exception was 10b (IC50 = 9.56 μM), 
and this was a consequence of the higher volume of the 4-(pyrrolidin-1-yl)pyridinium cationic head that dimin-
ished the π -cation interaction (Figure S2A) mentioned above.
Cancer-cell growth inhibition. All compounds were evaluated for their antiproliferative activity against 
a panel of nine different human tumor-cell lines (Table 2). All were given GI50 values generally lower than 1 μM, 
some of them even at nanomolar concentrations. Only two compounds, i.e. 10d and 10e, registered GI50 values 
higher than 10 μM against all tested lines.
Compounds 10a, 10b, 10f, and 10l offered the best antiproliferative activities against all cell lines. In particu-
lar, 10a gave GI50 values ranging from 0.027 to 0.12 μM, although the best value was by 10f in MDA-MB-231 cell 
line (GI50 = 0.001 μM). Compared to quinolinium derivatives, in general the pyridinium moiety provided better 
results in all tested cell lines.
In the pyridinium family, the best results were found when the substitution was an alkyl or cycloalkylamine 
(10a-b). The switching of dimethylamine to pyrrolidine caused a curious decline in activity for the majority of 
cell lines (10b, GI50 = 0.042 μM to 4.5 μM). The replacement of this tertiary amine by a conjugate aromatic sys-
tem (4-(4-chloro-N-methylanilino)pyridinium, 10c) resulted in lower activity (GI50 = 2.1 μM to 7.3 μM). It bears 
noting that despite of their low lipophilicity (10a, clog P = −0.36 and 10b clog P = 0.36), the compounds 10a-b 
provided better results than did compound 10c (clog P = 1.8). This finding can be explained by the different mode 
to bind to enzymes of these compounds, as mentioned above.
Replacing the pyridinium system with quinuclidine as cationic head, such as compounds 10d and 10e, led to 
a total loss of activity in all cell lines. This result may be due to the very low lipophilicity of 10d-e (clog P = −1.01 
and −2.42 respectively) and to the low IC50 value.
Regarding the quinolinium family (10f-l), all compounds had GI50 in the range of submicromolar values, 10l 
being the best compound (0.007 μM for Jurkat cells). No differences in the activity were detected between the 
different substituents in the 4 position upon the quinolinium system, since 10f and 10l (with N-methylanilino 
and 4-pyrrolidine in the 4 position, respectively) offer the best antiproliferative activity over nearly all the cell 
lines. However, the presence or not of a chloro atom over the quinolinium system, seems to play a crucial role in 
inhibiting cell growth. The chloro atom provided not only a higher lipophilicity to these compounds, improving 
the passage through the plasma membrane, but also a larger volume that impaired the insertion in the choline 
binding site. In fact, compound 10f, which has an N-methylanilino group at the 4 position without any chloro 
atom, exhibited better antiproliferative activity than did compound 10h or 10g, which have a chloro atom in the 
quinolinium.
However, 10f registered a lower value of ChoKα 1 inhibition (IC50 = 6.86 μM) than 10g and 10h (IC50 = 3.27 
and 2.79 μM, respectively) with chloro in para position of the N-methylanilino system (10g) or in 7 position 
of quinolinium fragment (10h). The chloro atom provided lipophilicity and good results of enzyme inhibition 
but this lipophilicity can allow binding to other targets in the cancer cells. On the other hand, the presence of 
two chloro atoms make compound 10i too bulky to inhibit the enzyme (IC50 = 16.22 μM), strongly reducing the 
antiproliferative activity, and it is also more lipophilic (clog P = 4.23), and thus does not bind to other targets. In 
conclusion, among the quinolinium family, the compounds with an N-methylanilino system upon the 4 position 
(10f-i), 10f offers the best antiproliferative values but lower inhibition of the enzyme (6.85 μM). This could be due 
to a greater affinity of 10f by the enzyme in a whole cancer cell while the higher lipophicility of 10g-h could help 
them to be more suitable for binding to other targets. This highlights the need for a balance between lipophilicity, 
inhibitory activity of the enzyme isolated (affinity and selectivity), and antiproliferative activity for achieving 
successful results.
The insertion of chloro in position 7 as in compound 10k improves the activity. This suggests that although 
the enzymatic inhibitory activity is almost the same for these compounds (IC50 from 0.92 to 2.02 μM), the chloro 
leads to an appreciable increase in the antiproliferative activity (10j vs. 10k) in nearly all the cell lines.
Finally, 10a and 10l were the compounds with the best GI50 values in almost all the cell lines. The two belong 
to different subfamilies. The first one, 10a, has a residue of dimethylaminopyridinium as a cationic head which 
could offer the best volume to fit in a choline binding site, while the compound 10l has a residue of 7-Chloro-
4-pyrrolidinequinolinium which provides more lipophilicity to the quinolinium moiety, allowing the compound 
to cross the plasma membrane more easily.
Trypan blue exclusion assay. The cell viability in the presence of 10a was also evaluated by the trypan blue 
exclusion assay. The results depicted in Fig. 4 reflect that 10a significantly inhibited cell growth in three cell lines 
(Fig. 4 panel A Jurkat, Panel B = HeLa; panel C = MDA-MB-231) tested in a concentration-dependent manner, 
roughly confirming the results found with the MTT test (see Table 2). Notably, we observed that the inhibition of 
cell proliferation was not dependent on the presence of the molecule in the incubation medium. In fact, exper-
iments in which the cells treated with 10a were harvested, washed, and incubated with fresh medium without 
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10a proliferation continued to be inhibited, suggesting that the catalytic activity of the enzyme may have been 
irreversibly inhibited (Figure S5 of Supplementary information).
Effect of 10a in non-tumoral cells. We investigated the effect of the most active compound (10a) in 
non-tumoral cells e.g. human lymphocytes and human umbilical-vein endothelial cells (HUVEC) from healthy 
donors. As shown in Table 3, in general, in resting lymphocytes, fibroblasts, and HUVEC, compound 10a had 
lower toxicity compared to tumor cells. Instead, in lymphocytes stimulated with a mitogen (e.g. phytohematoag-
glutinin, Pha), the compound had cytotoxicity comparable to that seen in tumor cells, indicating a certain pref-
erence only towards proliferating cells. In this context, it bears noting that other choline kinase inhibitors such as 
MN58b or RSM932A presented low or reduced cytotoxicity in oncogene-transformed cells and in tumor cells, in 
agreement with previously published data44,48.
The crystal structure of the complex ChoKα1/10a shows that the compound binds to the cho-
line binding site. Although the docking studies clearly suggested that the compounds bind to the choline 
Figure 4. Cell viability evaluated by trypan blue count in Jurkat cells (A) HeLa cells (B) and MDA-MB-231  
(C) after incubation with the indicated concentrations of compound 10a. Data are presented as mean± SEM of 
three independent experiments.
Antiproliferative activitya GI50 (μM)
Comp PBL(resting) PBL(+Pha)b Human fibroblasts HUVEC
10a 1.5 ± 0.64 0.034 ± 0.007 5.8 ± 1.3 5.1 ± 0.43
10b 34.8 ± 15.6 1.88 ± 0.71 30.5 ± 9.6 n.d.
10f 1.4 ± 0.6 0.10 ± 0.03 9.8 ± 2.5 n.d.
10g 0.98 ± 0.25 0.55 ± 0.11 7.4 ± 2.4 10.4 ± 3.5
10h 1.0 ± 0.42 0.32 ± 0.03 3.7 ± 0.43 16.0 ± 6.6
10j 2.0 ± 0.24 0.095 ± 0.021 14.3 ± 1.2 n.d.
10k 2.1 ± 0.80 0.034 ± 0.007 3.2 ± 0.86 n.d.
10l 3.8 ± 0.55 0.49 ± 0.15 9.6 ± 1.3 11.4 ± 5.9
RSM932A 1.1 ± 0.09 0.23 ± 0.05 n.d 0.46 ± 0.047
MN58b 2.0 ± 0.4 0.15 ± 0.05 n.d. 2.1 ± 0.58
Table 3. In vitro inhibitory effects of selected compounds in non-tumoral cells. aGI50 = Compound 
concentration required to inhibit tumor-cell proliferation by 50% Values are the mean ± SEM for three 
independent experiments. n.d. not determined. bPha, Phytohematoagglutini.
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binding site (Fig. 3, Figures S2 and S3 in the Supplementary information), we carried out further crystallization 
experiments with the most active ChoKα 1 inhibitors, 10a and 10l, in order to compile more consistent data con-
cerning their binding mode (Fig. 5).
Despite the large number of trials, we managed to solve only the crystal structure of ChoKα 1 in complex with 
compound 10a at 1.45 Å (see Methods and Supplementary information, Table S2). The other compound (10l) was 
too hydrophobic (clog P = 2.36, Table 2) and therefore insoluble in the mother liquor.
For ChoKα 1/10a complex, successive iterative model building and refinement cycles were carried out to pro-
duce a final model with good refinement statistics (R = 0.197, Rfree = 0.218, Table S2).
The structure is a monomer formed by a small N-terminal and a large C-terminal domain. Whereas the ATP 
binding site is located in a cleft formed by N- and C-terminal domains, the choline binding site is found in a 
deep hydrophobic pocket. One molecule of compound 10a was visualized at the choline binding site with good 
electron density (Fig. 5a). One 1-benzyl-4-(dimethylamino)pyridinium fragment was deeply positioned within 
the pocket and established π -cation interactions with Trp423 and Trp420, whereas it set π -π interactions with 
Tyr333, Tyr354, Phe435, and Tyr440 (Fig. 5a). The second 1-benzyl-4-(dimethylamino)pyridinium moiety was 
directed towards the outside part of the choline binding site, where it established π -π and hydrophobic interac-
tions with residues Phe361 and Ile433, respectively (Fig. 5a).
When the crystal pose was compared with the docked one, few differences were found between the two, 
especially regarding the conformation that the first 1-benzyl-4-(dimethylamino)pyridinium fragment adopted 
(Supporting information, Figure S6).
Figure 5. (a) Active site of ChoKα 1 in complex with compound 10a. Unbiased difference electron density maps 
are shown at 2.2 σ . (b) Superimposition of 10a with HC-3 (PDB ID: 3G15) and compound 2 (PDB ID: 3ZM9). 
(c) Residues that stabilize the positive charge of the cationic head in the three superimposed ligands.  
(d) Residues that undergo the most notable conformational changes when compounds 2 or 10a bind to the 
choline binding site.
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This moiety was completely superimposed in the two poses, indicating the accuracy of the theoretical predic-
tions. Nevertheless, the second 4-(dimethylamino)pyridinium moiety was flipped almost 90° towards the residue 
Phe361 but not towards the residue Ile433, as the docking had predicted. The reason for this difference is that the 
pyridinium ring set π -π interactions with Phe361 in the crystal pose, increasing the stability of the ligand-protein 
complex.
Remarkably, the positive charge of the quaternary ammonium of the first 1-benzyl-4-(dimethylamino)pyrid-
inium fragment was positioned at the choline binding site in the same place as one of the previously reported 
ChoKα 1 inhibitors, such as compound 2 (PDB ID:4BR3) and HC-3 (PDB ID: 3G15) (Fig. 5b). This indicates that 
common residues should participate in the positive-charge stabilization regardless of the chemical nature of the 
spacer groups. As reflected in Fig. 5c, these residues are Tyr333, Tyr354, Trp420, and Trp423, which set parallel 
π -cation and π -π interactions with the quaternary ammonium and the aromatic rings of the 1-benzyl-4-(dimeth-
ylamino)pyridinium fragment. Nevertheless, depending on the spacer and the cationic head of the compounds, 
some conformational changes in some of these residues were observed. For instance, residues Trp420 and Tyr333 
underwent a noticeable retraction to open the hydrophobic cavity when compound 10a or compound 2 bound 
the protein in order to accommodate the positive charge of the cationic head (Fig. 5d).
10a and G1 phase cell-cycle arrest. Compound 10a induced a G1 arrest of the cell cycle, which occurred 
in a concentration-dependent manner in the three cell lines tested (Jurkat, MCF-7 and MDA-MB-231). Together 
with the G1 increase, a concomitant reduction was found in the S phase (Fig. 6). Notably, cells with hypodip-
loid DNA content, suggestive of activation of apoptotic signaling, were not detected (data not shown). Similar 
results were also found with the two lead compounds RSM932A and MN58b, suggesting a common mecha-
nism of action. Our results agree with the data of Granata et al.16 which showed that ChoKα downregulation 
in ovary-cancer cells inhibits cell proliferation without affecting survival signaling pathways whereas, a reduc-
tion in the S-phase, proportional to growth inhibition, was observed in cells knocked down for ChoKα 1. The 
cell cycle also showed a slight G1 cell-cycle arrest in silenced cells compared with controls. On the contrary, 
Sanchez-Lopez et al.15 showed that RSM932A and MN58b induce a significant decrease of the G1 phase in 
Figure 6. Percentage of cells in each phase of the cell cycle in Jurkat (Panels A), MCF-7 (Panel B) and 
MDA-MB231 cells (Panels C–E) treated with the indicated compounds at the indicated concentrations for 24 h. 
Cells were fixed and labeled with PI and analyzed by flow cytometry as described in the experimental section.
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breast- and colon-cancer cells without any alteration of the other phases of the cell cycle. It should be noted that 
these data correspond to a concentration (15 μM) higher than that used in the present study.
10a induces low levels of apoptosis. To evaluate whether 10a causes cell death, we conducted a bipara-
metric cytofluorimetric analysis using PI, which stains DNA and enters only dead cells, together with fluorescent 
immunolabeling of the protein annexin-V, which binds to PS in a highly selective manner. Dual staining for 
annexin-V and with PI enables the discrimination between live cells (annexin-V−/PI−), early apoptotic cells 
(annexin-V+/PI−), late apoptotic cells (annexin-V+/PI+), and necrotic cells (annexin-V−/PI+). For a positive 
control, we used two well-known anticancer drugs such as Cis-Pt and Etoposide that in all cell lines tested induce 
significant apoptosis.
As depicted in Fig. 7, 10a after 72 h of incubation induced a modest increment in apoptotic cells only in Jurkat 
cells while both in MCF-7 and MDA-MB-231 the increase appeared not to be significantly different from that of 
the untreated cells.
Conclusions
In conclusion, the synthesis of a novel family of 1,1′ -(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(meth-
ylene))-bispyridinium or –bisquinolinium bromide (10a-l) and their evaluation as inhibitors of choline kinase 
against a panel of cancer-cell lines are described. These compounds were efficiently synthesized in three steps, 
starting from the building block 6. The chemistry used was appropriate to obtain the designed target compounds, 
and both the yield and the time of reaction were improved considerably with microwave irradiation.
Preliminary docking studies performed on both crystal structures, ChoKα 1/2 (PDB ID: 4BR3) and 
(ChoKα 1/4 PDB ID: 4CG8), and the analysis of the resulting poses, indicated that these compounds (10a-l) 
could adopt similar behaviour to that of compound 2 or to compound 4 thanks to the synclinal conformation of 
the linker that allowed the insertion of these molecules inside the Cho binding site and consequently enhanced 
the antiproliferative effect. The first experimental validation of the docking studies is shown with the results of 
tryptophan assays for these compounds, which offer very good Kd values. Among all the compounds, those 
belonging to the families of pyridinium and quinolinium offered similar or better IC50 ChoKα 1 than did the 
lead compounds MN58b and RSM932A. In fact, the best inhibitors were 10a and 10l, and the crystal structure 
of ChoKα 1/10a showed that the compound binds to the choline binding site, indicating the accuracy of the 
theoretical predictions, wherein the first one-benzyl- 4- (dimethylamino) pyridinium represents the appropriate 
fragment to inhibit the enzyme33.
Figure 7. Flow cytometric analysis of apoptotic cells after treatment of Jurkat (panel A), MCF-7 (panel B) and 
MDA-MB-231 (panel C) cells with 10a at the indicated concentrations after incubation for 72 h. The cells were 
harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry. As positive controls Cis-Pt 
and Etoposide (Eto) were used at the concentration of 50 μM and 5 μM, respectively. Data are represented as 
mean ± SEM of three independent experiments.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:23793 | DOI: 10.1038/srep23793
Also, we have shown these compounds to have an excellent antiproliferative profile, better than that of the two 
lead compounds RSM932A and MN58b in a panel of human tumor-cell lines. More importantly, our compounds 
presented lower or reduced toxicity in some non-tumor-cell lines in comparison to transformed cells. Indeed our 
results agree with previous observations indicating increased ChoKα 1 activity in cell cultures treated with growth 
factors or insulin23,49,50.
In this context it is important to note that our results indeed confirm these previous findings, and compound 
10a in fact presented higher activity only in rapidly proliferating cells such as mitogen-stimulated lymphocytes 
in comparison to quiescent cells.
Another important finding is that 10a significantly arrested the cell cycle in G1 together with a sharp reduc-
tion of the S phase, confirming their ability to inhibit cell growth. Curiously, despite their ability to block cell 
proliferation, 10a induced a low proportion of cell death, as reflected by a low level of Annexin-V positive cells 
(Fig. 7). Notably, this occurred also for the two reference compounds RSM932A and MN58b, which even at the 
maximum concentration used showed a negligible percentage of apoptotic cells, according to the analysis of the 
cell cycle. It is important to note that, although some reports26 indicate these two compounds may induce apop-
tosis, this takes place at concentrations much higher than the IC50 (15 μM), which can have an off-target effect.
This intriguing aspect is under active investigation by our group. Nevertheless, our data demonstrate that 
10a is a highly promising new Chokα 1 inhibitor and is worthy of further preclinical evaluation as a potential 
anticancer drug.
Methods
Chemistry. General procedure C for the synthesis of the final compounds 10a-l. A solution of 1eq 1,2-bis 
(4-bromomethylphenoy)ethane (8) in dry CH3CN was added drop by drop to a solution of 9a-l (2 eq) in dry 
CH3CN under argon conditions. The mixture was heated under reflux for a 3 additional days and, after cooling 
down to room temperature, washed with diethyl ether and hexane, filtered, and dried under vacuum to afford 
10a-l as a solid product.
Characterization data for final products are described below. 1,1′-(((ethane-1,2-diylbis(oxy))
bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) bromide (10a). Following general 
procedure C furnished 10a as a yellow solid, yield 42%, mp: 62–63 °C. 1H NMR (300 MHz, CD3OD) δ: 8.20 
(d, J = 7.86 Hz, 4H), 7.35 (d, J = 8.73 Hz, 4H), 7.02 (d, J = 8.73 Hz, 4H), 6.99 (d, J = 7.86 Hz, 4H), 5.30 (s, 4H), 4.33 
(s, 4H), 3.24 (s, 12H). 13C RMN (75 MHz, CD3OD) δ: 161.80 × 2, 158.87 × 2, 143.76 × 4, 131.98 × 4, 129.20 × 2, 
117.30 × 4, 109.93 × 4, 68.86 × 2, 62.22 × 2, 41.20 × 4. HRMS (m/z): [M]2+ calcd for C30H36N4O2: 242.1419, 
found: 242.1409.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(pyrrolidin-1-yl)pyridinium) bromide 
(10b). Following general procedure C furnished 10b as a brown solid, yield 48%, mp: 129–130 °C. 1H NMR 
(300 MHz, CD3OD) δ: 8.17 (d, J = 7.77 Hz, 4H), 7.34 (d, J = 8.73 Hz, 4H), 7.01 (d, J = 8.73 Hz, 4H), 6.84 
(d, J = 7.77 Hz, 4H), 5.28 (s, 4H), 4.32 (s, 4H), 3.54 (t, J = 6.84 Hz, 8H), 2.11 (t, J = 6.86 Hz, 8H), 13C NMR 
(75 MHz, CD3OD) δ: 161.79 × 2, 156.05 × 2, 143.68 × 4, 131.92 × 4, 129.31 × 2, 117.29 × 4, 110.51 × 4, 68.86 × 2, 
62.26 × 2, 50.28 × 4, 26.98 × 4. HRMS (m/z): [M]2+ calcd for C34H40N4O2: 268.1576, found: 268.1568.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)pyridin-
ium) bromide (10c). Following general procedure C furnished 10c as a white solid, yield 30%, mp: >300 °C. 1H 
NMR (600 MHz, CD3OD) δ: 8.28 (d, J = 8.5 Hz, 4H), 7.58 (d, J = 8.5 Hz, 4H), 7.37 (m, 8H), 7.02 (d, J = 8.4 Hz, 
4H), 6.92 (m, 4H), 5.35 (s, 4H), 4.33 (s, 4H), 3.53 (s, 6H). 13C NMR (75 MHz, CD3OD) δ: 160.85 × 2, 158. 31 × 2 
143.52 × 4, 135.52 × 2, 131.94 × 4, 131.13 × 4, 129.28 × 4, 127.95 × 2, 116.27 × 8, 110.27 × 2, 67.81 × 2, 61.64 × 2, 
30.55 × 2. HRMS (m/z): [M]2+ Calcd for C20H19N2OCl: 338.1186, found: 338.1194.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(quinuclidinium) bromide (10d). Following 
general procedure C furnished 10d as a white solid, yield 56%, mp: >300 °C. 1H NMR (300 MHz, CD3OD) δ: 
7.47 (d, J = 8.78 Hz, 4H), 7.13 (d, J = 8.78 Hz, 4H), 4.43 (s, 4H), 4.35 (s, 4H), 3.48 (m, 12H), 2.18 (dt, J = 6.44, 
3.23 Hz, 2H), 2.01 (dt, J = 8.23, 3.23 Hz, 12H). 13C NMR (75 MHz, CD3OD) δ: 162.80 × 2, 136.48 × 4, 121.54 × 2, 
117.14 × 4, 69.52 × 2, 68.87 × 2, 56.39 × 6, 25.81 × 6, 22.33 × 2. HRMS (m/z) [M]2+ calcd for C30H42N2O2: 
231.1623, found: 231.1628.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(3-hydroxyquinuclidinium) bromide 
(10e). Following general procedure C furnished 10e as a white solid, yield 63%, mp: 268–270 °C. 1H NMR (300 MHz, 
DMSO-d6) δ: 7.48 (d, J = 8.66 Hz, 8H), 7.13 (d, J = 8.66 Hz, 8H), 4.43 (s, 8H), 4.41 (s, 8H), 4.08, 3.64, 3.35, 3.04, 2.27, 
2.10 (6m, 52H), 13C NMR (75 MHz, DMSO-d6) δ: 159.52 × 4, 134.43 × 8, 119.63 × 4, 114.77 × 8, 65.61 × 4, 62.26 66.37, 
63.27, 53.46, 52.52, 26.83, 20.87, 17.29 × 4. HRMS (m/z) [M]2+ calcd for C30H42N2O4: 247.1572, found: 247.1565.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(methyl(phenyl)amino)quinolinium) bro-
mide (10f). Following general procedure C furnished 10f as a yellow solid, yield 64%, mp: 169–170 °C. 1H NMR 
(300 MHz, CD3OD) δ: 8.86 (d, J = 7.44 Hz, 2H), 8.13 (d, J = 8.37 Hz). 7.81 (dt, J = 5.57, 1.43 Hz, 2H), 7.62 (dd, J = 8.8, 
1.3 Hz, 2H), 7.53 (m, 4H), 7.46 (t, J = 7.36 Hz, 2H), 7.40–7.29 (m, 12H), 7.03 (d, J = 8.76 Hz, 4H), 5.89 (s, 4H), 4.33 (s, 
4H), 3.84 (s, 6H). 13C NMR (75 MHz, CD3OD) δ: 161.47 × 2, 160.80 × 2, 150.14 × 2, 148.54 × 2, 141.68 × 2, 135.51 × 2, 
132.75 × 4, 130.63 × 4, 130.28 × 2, 130.15 × 2, 128.64 × 2, 127.85 × 2, 127.73 × 4, 122.29 × 2, 120.97 × 2, 117.30 × 4, 
107.73 × 2, 68.85 × 2, 59.94 × 2, 46.75 × 2. HRMS (m/z) [M]2+ calcd for C48H44N4O2: 354.1732, found: 354.1736.
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1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)quinolin-
ium) bromide (10g). Following general procedure C furnished 10g as a yellow solid, yield 70%, mp: 178–180 °C. 
1H NMR (400 MHz, CD3OD) δ: 8.90 (d, J = 7.40 Hz, 2H), 8.16 (dd, J = 8.9, 0.6 Hz, 2H), 7.84 (dt, J = 5.64, 1.36 Hz, 
2H), 7.67 (dd, J = 8.8, 1.2 Hz, 2H), 7.52 (d, J = 8.91 Hz, 4H), 7.41–7.37 (m, 8H), 7.33 (d, J = 8.77 Hz, 4H), 7.03 (d, 
J = 8.77 Hz, 4H), 5.91 (s, 4H), 4.33 (s, 4H). 3.82 (s, 6H), 13C NMR (75 MHz, CD3OD) δ: 161.48 × 2, 160.92 × 2, 
148.81 × 2, 148.77 × 2, 141.68 × 2, 135.68 × 2, 135.58 × 2, 132.72 × 4, 130.69 × 4, 130.00 × 2, 129.28 × 4, 
128.52 × 2, 128.20 × 2, 122.41 × 2, 121.13 × 2, 117.30 × 4, 108.36 × 2, 68.84 × 2, 60.09 × 2, 46.53 × 2. HRMS 
(m/z) [M]2+ calcd for C48H42N4O2Cl2: 388.1342, found: 388.1338.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(methyl(phenyl)amino)quin-
olinium) bromide (10h). Following general procedure C furnished the crude residue which was purified by 
flash chromatography using CH2Cl2: MeOH (9:1 v/v) as eluent to obtain 10h as a yellow-green solid, yield 61%, 
mp: 181–183 °C. 1H NMR (300 MHz, CD3OD) δ: 8.82 (d, J = 7.50 Hz, 2H), 8.15 (d, J = 1.89 Hz, 2H), 7.56–7.53 
(m, 6H), 7.47 (t, J = 7.4 Hz, 2H), 7.41–7.40 (d, J = 7.48 Hz, 4H), 7.34–7.31 (m, 6H), 7.29 (dd, J = 9.3, 1.9 Hz, 2H), 
7.06–7.03 (d, J = 8.70 Hz, 4H), 5.85 (s, 4H), 4.34 (s, 4H), 3.82 (s, 6H, CH3). 13C NMR (75 MHz, CD3OD) δ: 
161.58 × 2, 160.51 × 2, 149.76 × 2, 148.95 × 2, 142.51 × 2, 141.90 × 2, 132.92 × 4, 131.80 × 2, 130.77 × 4, 
130.59 × 2, 128.35 × 2, 128.24 × 2, 127.72 × 4, 128.24 × 2, 120.68 × 2, 120.45 × 2, 117.41 × 4, 107.93 × 2, 
68.86 × 2, 59.91 × 2, 46.87 × 2. HRMS (m/z): [M]2+ calcd for C48H42N4O2Cl2: 388.1342, found: 388.1331.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-((4-chlorophenyl)(methyl)amino)
quinolinium) bromide (10i). Following general procedure C furnished the crude residue which was purified 
by flash chromatography using CH2Cl2: MeOH (9:1 v/v) as eluent to obtain 10i as a yellow solid, yield 39%, mp: 
185–186 °C, 1H NMR (300 MHz, CD3OD) δ: 8.87 (d, J = 7.46 Hz, 2H), 8.20 (d, J = 1.93 Hz, 2H), 7.63 (d, 
J = 9.31 Hz, 2H), 7.55 (d, J = 8.78 Hz, 4H), 7.42 (d, J = 8.78 Hz, 4H), 7.40 (d, J = 1.96 Hz, 2H), 7.38 (d, J = 7.47 Hz, 
2H), 7.35 (d, J = 8.73 Hz, 4H), 7.06 (d, J = 8.73 Hz, 4H, H-2), 5.88 (s, 4H), 4.35 (s, 4H), 3.82 (s, 6H, CH3). 13C 
NMR (75 MHz, CD3OD) δ: 161.59 × 2, 160.65 × 2, 149.22 × 2, 148.45 × 2, 142.50 × 2, 142.06 × 2, 135.92 × 2, 
132.88 × 4, 131.68 × 2, 130.85 × 4, 129.33 × 4, 128.71 × 2, 128.15 × 2, 120.82 × 2, 120.61 × 2, 117.40 × 4, 
108.57 × 2, 68.85 × 2, 60.05 × 2, 46.69 × 2. HRMS (m/z) [M]2+ calcd for C48H40N4O2Cl4: 422.0953, found: 
422.0952.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)quinolinium) bromide 
(10j). Following general procedure C furnished 10j as a yellow solid, yield 67%, mp: 75–77 °C. 1H RMN 
(300 MHz, CD3OD) δ: 8.54 (d, J = 7.73 Hz, 2H), 8.42 (dd, J = 8.62, 1.28 Hz, 2H), 8.05 (dd, J = 8.83, 1.05 Hz, 2H), 
7.90 (dt, J = 5,67, 1,33 Hz, 2H), 7.66 (dt, J = 5.77, 1.15 Hz, 2H), 7.27 (d, J = 8.80 Hz, 4H), 7.10 (d, J = 7.74 Hz), 
7.00 (d, J = 8.80 Hz, 4H), 5.74 (s, 4H), 4.30 (s, 4H), 4.09 (m, 8H), 2.09 (m, 8H), 1.75 (dt, J = 5.40, 2.54 Hz, 8H), 
13C NMR (75 MHz, CD3OD) δ: 161.91 × 2, 161.34 × 2, 146.48 × 2, 142.10 × 2, 135.52 × 2, 130.48 × 4, 130.44 × 2, 
128.98 × 2, 127.04 × 2, 121.41 × 2, 120.33 × 2, 117.22 × 4, 104.55 × 2, 68.84 × 2, 58.99 × 2, 56.06 × 4, 29.37 × 4, 
29.23 × 4. HRMS (m/z) [M]2+ calcd for C46H52N4O2: 346.6700, found 346.2039.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)-7-chloroquinolinium) bro-
mide (10k). Following general procedure C furnished the crude residue which was purified by flash chroma-
tography using CH2Cl2: MeOH (8:1 v/v) as eluent to obtain 10k as a white solid, yield 41%, mp: 87–88 °C. 1H 
RMN (400 MHz, CD3OD) δ: 8.51 (d, J = 7.75 Hz, 2H), 8.40 (d, J = 9.21 Hz, 2H), 8.07 (d, J = 1.82 Hz, 2H), 7.29 (d, 
J = 8.64 Hz, 4H), 7.65 (dd, J = 9.2, 1.9 Hz, 2H), 7.11 (d, J = 7.78 Hz, 2H), 7.03 (d, J = 8.64 Hz, 4H), 5.72 (s, 4H), 
4.33 (s, 4H), 4.08 (m, 8H), 2.08 (m, 8H), 1.74 (m, 8H). 13C NMR (75 MHz, CD3OD) δ :161.56 × 2, 161.44 × 2, 
146.77 × 2, 142.95 × 2, 141.82 × 2, 132.31 × 2, 130.59 × 4, 128.57 × 2, 127.45 × 2, 119.88 × 2, 119.78 × 2, 
117.32 × 4, 105.00 × 2, 68.85 × 2, 59.00 × 2, 56.12 × 4, 29.28 × 4, 29.16 × 4. HRMS (m/z) [M-Br]+ calcd for 
C46H50N4O2Cl2Br : 839.24949, found: 839.2494.
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(pyrrolidin-1-yl)quinolinium) 
bromide (10l). Following general procedure C furnished the crude residue which was purified by flash chro-
matography using CH2Cl2: MeOH (9:1 v/v) as eluent to obtain 10l as a white solid, yield 48%, mp: 118–120 °C. 
1H RMN (300 MHz, CD3OD) δ: 8.63 (d, J = 9.23 Hz, 2H), 8.51 (d, J = 7.69 Hz, 2H), 8.04 (d, J = 2.02 Hz, 2H), 7.66 
(dd, J = 9.2, 2.0 Hz, 2H), 7.27 (d, J = 8.75 Hz, 4H), 7.01 (d, J = 8.75 Hz, 4H), 6.90 (d, J = 7.69 Hz, 2H), 5.71 (s, 
4H), 4.32 (s, 4H), 4.02 (m, 8H), 2.20 (m, 8H). 13C NMR (75 MHz, CD3OD) δ: 161.37 × 2, 157.92 × 2, 146.91 × 2, 
142.45 × 2, 141.76 × 2, 131.76 × 2, 130.45 × 4, 128.68 × 2, 127.71 × 2, 120.16 × 2, 119.73 × 2, 117.29 × 4, 
104.64 × 2, 68.83 × 2, 59.06 × 2, 55.43 × 4, 24.64 × 4. HRMS (m/z) [M]2+ calcd for C42H42N4O2Cl2: 352.1337, 
found: 352.1353.
Docking Studies. Molecular-modeling studies were performed by using Sybyl program51. Crystal structures 
of human ChoKα 1 in complex with compounds 2 (PDB entry 4BR3) and 4 (PDB entry 4CG8) were used for 
docking studies. In both cases, using the Structure Preparation Tool module of Sybyl refined protein structure. 
Missing side chains of those residues situated far away from the binding sites were added and protein N-terminal 
and C-terminal were fixed with ACE and NME, respectively. Hydrogens and charges were also added and proto-
nation type of Glu, Asp, Gln and Asp was analyzed and fixed. Hydrogen orientations were also checked in order 
to maintain intramolecular hydrogen bonds within the protein. Finally, the molecules of compounds 2 and 4 
inserted into the ATP binding site were carefully checked to assure the correction of these molecules. Structures 
of compounds 10a-l were constructed from standard fragments of the Libraries of the Sybyl program, and used 
as ligands for docking studies. As previously described52, a new type of atom was necessary to define in order to 
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build the molecules: N.ar4, the quaternary nitrogen of the pyridinium fragments. Additional parameters were 
also developed from initio calculations to optimize the geometry of these molecules Atomic charges were calcu-
lated by means of Gaussian Program53 and optimizations were undertaken using the BFGS method.
The Surflex-Dock54, module implemented in the Sybyl program was used for docking studies. Surflex Dock 
Protomol was prepared using compound 2 or 4 inserted into the ChoK binding site, with a threshold value of 
0.5 and a Bloat of 0 A. Surflex-Dock GeomX (SFXC) protocol was used, the search grid was expanded in 5 Å, 50 
additional starting conformations were used for each molecule and 30 conformations per fragment. The results 
were analyzed using the Sybyl program and the most stable pose for each molecule was chosen as the preferred 
one inside the ChoK enzyme. Figures were built using the PyMOL program55.
Biological experiments
Materials and Methods. [methyl-14C]choline chloride (55 mCi/mmol) was supplied by Perkin Elmer 
(Massachusetts, USA). Fetal bovine serum (FBS) was from The Cell Culture Company (Pasching, Austria). 
Minimal essential medium (MEM) was from Sigma-Aldrich (Madrid, Spain). Cell proliferation reagent WST-1 
was from Roche Applied Sciences (Mannhein, Germany). Thin-layer chromatography (TLC) plates of Silica Gel 
60 A were acquired from Analtech (Newark, DE, USA). Microwell plates and culture dishes were obtained from 
NuncTM (Langenselbold, Germany). All other reagents were of analytical grade.
Determination of Human choline kinase α1 (ChoKα1) activity. The effect of the different inhibitors 
on human choline kinase (ChoK) was assayed in ChoKα 1 purified as previously described32. In each experiment 
DMSO-assays were always run in parallel as a control. DMSO in no case exceeded a concentration of 0.1% in 
order to avoid unspecific ChoK inhibition. ChoK activity was assayed by measuring the rate of incorporation of 
14C from [methyl-14C]choline into phosphocholine both in the presence or absence of different inhibitor concen-
trations. Briefly, the final reaction mixture contained 100 mM Tris (pH 8.5), 10 mM MgCl2, and 10 mM ATP, and 
20 ng of purified ChoKα 1. After the samples were preincubated at 37 °C for 5 min, the reaction was initiated with 
1 mM [methyl-14C]choline (4500 dpm/nmol) and incubated at 37 °C for 10 min, the final volume being 55 μl. The 
assay was stopped by immersing the reaction tubes in boiling water for 3 min. Aliquots of the reaction mixture 
were applied to the origin of Silica Gel plates in the presence of phosphocholine (0.1 mg) and choline (0.1 mg) as 
carriers. The chromatography was developed in methanol/0.6% NaCl/28% NH4OH in water (50:50:5, v/v/v) as 
solvent. Phosphocholine was visualized under exposure to iodine vapor and the corresponding spot was scraped 
and transferred to scintillation vials for measurement of radioactivity by a Beckman 6000-TA (Madrid, Spain) 
liquid-scintillation counter. At least three experiments were performed in all assays. The 50% inhibitory concen-
trations (IC50 values) were determined from the % activity of the enzymes at different concentrations of synthetic 
inhibitors by using a sigmoidal dose-response curve (the ED50plus v1.0 software).
Cloning and purification of ChoKα1. Details on cloning and purification of human ChoKα 1 have been 
previously reported32.
Tryptophan fluorescence quenching. All compounds were prepared in 100% DMSO. Their Kds against 
human ChoKα 1 were measured by monitoring the quenching of tryptophan fluorescence. All experiments were 
performed in a Cary Eclipse spectrofluorometer (Varian) at 25 °C with the enzymes at 1 μM, and concentrations 
of compounds varying from 0.1 to 5 μM for ChoKα 1 in 25 mM Tris, 150 mM NaCl, pH 7.5. Fluorescence emis-
sion spectra were recorded in the 300–400 nm range with an excitation wavelength of 280 nm, with slit width of 
5 nm. Controls were determined by incubating the enzymes with equivalent amounts of DMSO. As indicated 
previously, data analysis was performed in Prism (GraphPad software) considering a model with a single bind-
ing site (Eq. 1), where F0 is the intrinsic fluorescence of the enzyme in the absence of quencher (Q), F1 is the 
observed fluorescence at a given quencher concentration, fa is the fractional degree of fluorescence, and Kd is the 
dissociation constant.
− =
∗
+
F
F
fa Q
kd Q
1 1
0
[ ]
[ ] (1)
Protein crystallography. ChoKα 1 at 20 mg/ml in buffer 25 mM Tris/HCl, 150 mM NaCl pH 7.5 was used 
as the protein solution. The sitting-drop vapor-diffusion method was used to produce apo-crystals by mixing 
0.5 μl of the protein solution and an equal volume of mother liquor (crystals appeared in 20% polyethylene glycol 
[PEG] 3350 and 0.25 M potassium isothiocyanate). Tetragonal crystals (space group P43212) grew within in 3–4 
days and were soaked in 2 μL of the mother liquor with 0.2 μL of a dilution 500 mM of compounds 10a, 10g, 10h, 
10k, and 10l in DMSO (DMSO was at 10% final concentration in the mix whereas compounds were at 50 mM) 
for two days. Only crystals soaked with compound 10a contained the compound. The crystals used in this study 
were cryoprotected in mother-liquor solutions containing 20% ethylenglycol and frozen in a nitrogen gas stream 
cooled to 100 K.
Diffraction data of the binary complexes were collected at beamline I04-1 (Diamond, Oxford). The data 
was processed and scaled using the XDS package and CCP4 software, relevant statistics are given in Table S2 of 
Supplementary information
Structure determination and refinement. The structure of the binary complex was solved by molec-
ular replacement using PDB ID 3G15 as a template. Initial phases were further improved by cycles of manual 
model building in Coot and refinement with REFMAC5. The final model was validated with PROCHECK, model 
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:23793 | DOI: 10.1038/srep23793
statistics are given in Table S2 of the supplemental information section. Coordinates and structure factors have 
been deposited in the Worldwide Protein Data Bank (wwPDB, and see Table S2 for the pdb code).
Antiproliferative assays in cancer cells. Human T-cell leukemia (Jurkat), human B-cell leukemia (RS 
4,11) and human promyelocytic leukemia (HL-60) cells were grown in RPMI-1640 medium (Gibco, Milan, Italy). 
Breast adenocarcinoma (MCF-7 and MDA-MB-231), human non-small cell lung carcinoma (A549), human cer-
vix carcinoma (HeLa), human prostate adenocarcinoma (PC-3), and human colon adenocarcinoma (HT-29) 
cells were grown in DMEM medium (Gibco, Milan, Italy). Both media were supplemented with 115 units/mL 
of penicillin G (Gibco, Milan, Italy), 115 μg/mL of streptomycin (Invitrogen, Milan, Italy) and 10% fetal bovine 
serum (Invitrogen, Milan, Italy). Stock solutions (10 mM) of the different compounds were obtained by dissolv-
ing them in DMSO. Individual wells of 96-well tissue-culture microtiter plates were inoculated with 100 μL of 
complete medium containing 8 × 103 cells. The plates were incubated at 37 °C in a humidified 5% CO2 incubator 
for 18 h prior to the experiments. After medium removal, 100 μL of fresh medium containing the test compound 
at different concentrations was added to each well and incubated at 37 °C for 72 h. The percentage of DMSO in 
the medium in no case exceeded 0.25%. Cell viability was assayed by the (3-(4,5-dimethylthiazol-2-yl)-2,5-dip
henyl tetrazolium bromide test as previously described56. The GI50 was defined as the compound concentration 
required to inhibit cell proliferation by 50%, in comparison with cells treated with the maximum amount of 
DMSO (0.25%) and considered as 100% viability. In additional experiments, cell viability was also determined by 
calculating the values of trypan blue positive cells (dead cells) and trypan blue negative (live cells) from a mixture 
of the cell suspension and 0.4% trypan blue solution.
Antiproliferative assays in non-tumoral cells. Peripheral mononuclear cells (PBMC) from healthy 
donors were obtained by separation on Lymphoprep (Fresenius KABI Norge AS) gradient. After extensive wash-
ing, cells were resuspended (1 × 106 cells/mL) in RPMI-1640 with 10% fetal bovine serum and incubated over-
night. For cytotoxicity evaluations in proliferating PBL cultures, non-adherent cells were resuspended at 5 × 105 
cells/mL in growth medium, containing 2.5 μg/mL PHA (Irvine Scientific). Different concentrations of the test 
compounds were added, and viability was determined 72 h later by the MTT test. For cytotoxicity evaluations in 
resting PBL cultures, non-adherent cells were resuspended (5 × 105 cells/mL) and treated for 72 h with the test 
compounds, as described above.
Human Umbilical Vein Endothelial cells (HUVEC), were prepared from human umbilical-cord veins, as pre-
viously described57. The adherent cells were maintained in M200 medium added by LSGS (low serum growth sup-
plement), containing FBS, hydrocortisone, hEGF, bFGF, heparin, gentamycin/amphotericin (Life Technologies, 
Monza, Italy). Once confluent, the cells were detached by trypsin–EDTA solution and used in experiments from 
the first to sixth passages.
Human fibroblasts from foreskin were isolated as previously described58 and maintained in DMEM medium 
with 10% fetal bovine serum added.
Cell-cycle distribution analysis. For flow-cytometric analysis of the DNA content, 5 × 105 HeLa or Jurkat 
cells in exponential growth were treated with different concentrations of the test compounds for 24 and 48 h. 
After the incubation period, the cells were collected, centrifuged, and fixed with ice-cold ethanol (70%). The cells 
were then treated with lysis buffer containing RNAse A and 0.1% Triton X-100, and then stained with propidium 
iodide (PI). Samples were analyzed in a Cytomics FC500 flow cytometer (Beckman Coulter). DNA histograms 
were analyzed using MultiCycle for Windows (Phoenix Flow Systems).
Annexin-V/PI assay. Surface exposure of PS on apoptotic cells was measured by flow cytometry with 
Cytomics FC500 (Beckman Coulter) by adding simultaneously annexin-V conjugated to fluorescein isothiocy-
anate (FITC) and PI to cells according to the manufacturer′ s instructions (Annexin-V Fluos, Roche Diagnostic).
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